Copper-Based Drug Could Open New Path for Alzheimer's Therapy

A copper-based drug compound is considered capable of opening a new direction in the management of Alzheimer’s disease. In laboratory studies, researchers reported that a compound named Cu(ATlam) is able to reduce toxic protein levels in the brain while simultaneously improving memory capabilities.

Researchers from Monash University reported that Cu(ATSM) not only reduces levels of amyloid-beta, a protein strongly associated with Alzheimer’s, but also enhances long-term spatial memory. The findings, published in ACS Chemical Neuroscience, highlight a therapeutic approach that targets the brain’s natural waste disposal system.

This approach is crucial because, in Alzheimer’s, the brain’s ability to clear harmful substances is known to decline. Consequently, toxic proteins such as amyloid-beta can accumulate and disrupt cognitive functions.

Alzheimer’s develops, among other factors, due to the accumulation of amyloid-beta in the brain. Under normal conditions, these proteins can be cleared through the blood-brain barrier, a protective layer that regulates which substances can enter and exit the brain.

However, in Alzheimer’s patients, this system can become less efficient. When the clearance process weakens, harmful proteins can more easily accumulate, potentially worsening brain dysfunction.

In this process, the P-glycoprotein pump, or P-gp, plays a vital role. P-gp is a transporter protein that helps move waste from the brain into the bloodstream. When the function of this pump declines, the brain’s ability to clear toxic material also decreases.

The study shows that Cu(ATSM) has the potential to help restore this clearance system by increasing the number and activity of P-gp pumps. The study’s lead author, Dr Jae Pyun, explained that the therapy works by improving the function of brain blood vessels, which is linked to the reduction of toxic protein levels and improved cognitive performance.

“This is the first study to show that Cu(ATSM) can increase the abundance of the P-gp clearance pump in Alzheimer’s models by 24.1 percent, effectively linking the improvement of the blood-brain barrier with the reduction of toxic proteins and increased cognitive function,” said Dr Pyun.

The research team also reported that the restoration of this waste disposal pathway had a measurable impact. Over a period of 56 days, this therapy was reported to reduce toxic amyloid-beta by 42 percent and increase spatial learning by nearly 44 percent.

“By repairing the pump, the brain can finally clear the trapped waste,” the research team stated.

These results suggest that repairing the blood-brain barrier could be one of the keys to slowing or partially reducing the damage seen in Alzheimer’s. Nevertheless, these findings are still at the laboratory stage and have not yet provided evidence of clinical benefits in humans.

The study’s senior author, Professor Joseph Nicolazzo, stated that Cu(ATSM) could potentially move towards human trials faster than some other experimental therapies. This is because the compound has already entered clinical testing for other neurological conditions.

“Cu(ATSM) is a copper compound with anti-inflammatory and neuroprotective properties that has progressed to clinical testing for conditions such as Parkinson’s and ALS,” said Nicolazzo.

According to Nicolazzo, reducing the amyloid burden in the brain is a meaningful target for improving symptoms. He believes these preclinical results support the rationale for testing Cu(ATSM) on early-stage Alzheimer’s patients who are already showing symptoms.

“Because the reduction of amyloid burden has been clinically proven to improve functional outcomes, these preclinical results strongly support the basis for testing this drug on symptomatic early-stage Alzheimer’s disease,” he said.

While these findings are promising, researchers still need to understand in more detail how amyloid-beta exits the brain after the blood-brain barrier is repaired. One theory suggests that Cu(ATSM) may also increase the activity of microglia, which are immune cells in the brain that help break down toxic proteins.

Dr Dayan Goodenowe, a neuroscientist not directly involved in the study, assessed that targeting the blood-brain barrier and the waste disposal system is a promising field. In his view, Alzheimer’s is not merely a matter of plaque accumulation in the brain.

“Alzheimer’s involves the ageing biological environment of the brain, including membrane biology, inflammation, vascular function, lipid metabolism, and cellular resilience,” said Goodenowe.

He emphasised that any single mechanism must still be validated before it can be determined whether the approach truly provides meaningful clinical benefits.

“The key question is not just whether amyloid changes, but whether the intervention improves cognition, function, and outcomes in humans,” he added.

Goodenowe added that research needs to move from the mechanistic and preclinical stages towards the evaluation of safety, dosage, effectiveness, and clinical validation in humans.

These findings highlight the possibility of therapeutic strategies that do not only focus on amyloid-beta proteins but also on the function of brain blood vessels and the protein waste clearance system. In other words, repairing the brain’s natural waste disposal system could be a vital part of developing future Alzheimer’s therapies.

Further studies are required to ensure the pathway of Cu(ATSM) action, its safety, the correct dosage, and whether the benefits observed in laboratory models can be translated into real improvements in human patients.

For now, Cu(ATSM) offers an exciting early signal: future Alzheimer’s therapies may not only target protein accumulation but also repair the biological systems intended to clear those proteins from the brain.